Find a Researcher

Novel Antimurine Thyroid-Stimulating Hormone Receptor Monoclonal Antibodies. Monoclon Antib Immunodiagn Immunother. 2023 Jun; 42(3):109-114.
View in: PubMed

Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 Jun; 618(7966):E27.
View in: PubMed

PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity. Nat Commun. 2023 05 17; 14(1):2806.
View in: PubMed

Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 May; 617(7960):377-385.
View in: PubMed

PI3Kß controls immune evasion in PTEN-deficient breast tumours. Nature. 2023 May; 617(7959):139-146.
View in: PubMed

mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nat Commun. 2023 03 03; 14(1):1214.
View in: PubMed

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proc Natl Acad Sci U S A. 2023 02 07; 120(6):e2219199120.
View in: PubMed

mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection. J Clin Invest. 2023 01 17; 133(2).
View in: PubMed

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. J Immunother Cancer. 2023 01; 11(1).
View in: PubMed

Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. Sci Adv. 2022 12 09; 8(49):eabq6527.
View in: PubMed

Immunoregulatory effects of RGMb in gut inflammation. Front Immunol. 2022; 13:960329.
View in: PubMed

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature. 2022 10; 610(7930):173-181.
View in: PubMed

Preclinical models for development of immune-oncology therapies. Immuno-oncol Insights. 2022; 3(8):379-398.
View in: PubMed

Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function. EBioMedicine. 2022 Oct; 84:104254.
View in: PubMed

Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2022 09 15; 28(18):4045-4055.
View in: PubMed

PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques. Proc Natl Acad Sci U S A. 2022 08 16; 119(33):e2202148119.
View in: PubMed

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. Monoclon Antib Immunodiagn Immunother. 2022 Aug; 41(4):202-209.
View in: PubMed

Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells. Cell Metab. 2022 08 02; 34(8):1137-1150.e6.
View in: PubMed

Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. Cancer Immunol Res. 2022 06 03; 10(6):680-697.
View in: PubMed

The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings. Front Immunol. 2022; 13:773946.
View in: PubMed

Soluble PD-L1 as an early marker of progressive disease on nivolumab. J Immunother Cancer. 2022 02; 10(2).
View in: PubMed

Anti-CAIX BB? CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. Mol Ther Oncolytics. 2022 Mar 17; 24:385-399.
View in: PubMed

Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunol Res. 2021 12; 9(12):1465-1475.
View in: PubMed

PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue. Sci Immunol. 2021 Sep 10; 6(63):eabh3034.
View in: PubMed

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nat Cancer. 2021 05; 2(5):503-514.
View in: PubMed

Emerging concepts in PD-1 checkpoint biology. Semin Immunol. 2021 02; 52:101480.
View in: PubMed

Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 05 01; 106(5):1330-1342.
View in: PubMed

Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021 06 03; 81(11):2317-2331.e6.
View in: PubMed

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 03 11; 137(10):1353-1364.
View in: PubMed

Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. Clin Cancer Res. 2021 05 15; 27(10):2816-2826.
View in: PubMed

Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
View in: PubMed

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021 06; 11(6):1524-1541.
View in: PubMed

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
View in: PubMed

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends Immunol. 2021 03; 42(3):209-227.
View in: PubMed

PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques. Sci Immunol. 2021 01 15; 6(55).
View in: PubMed

PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 2021 01 04; 218(1).
View in: PubMed

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res. 2021 01 01; 27(1):276-287.
View in: PubMed

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 02; 9(2):156-169.
View in: PubMed

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
View in: PubMed

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol. 2020 10 15; 21(1):263.
View in: PubMed

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020 09; 22(9):1064-1075.
View in: PubMed

The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. Cell Rep. 2020 06 30; 31(13):107827.
View in: PubMed

Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020 Jun 05; 6(1):19.
View in: PubMed

Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020; 6:19.
View in: PubMed

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
View in: PubMed

Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
View in: PubMed

Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020 03 17; 3(1):128.
View in: PubMed

The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020 04; 20(4):209-215.
View in: PubMed

Acidity changes immunology: a new VISTA pathway. Nat Immunol. 2020 01; 21(1):13-16.
View in: PubMed

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell. 2020 01 13; 37(1):37-54.e9.
View in: PubMed

Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis. J Transl Autoimmun. 2020; 3:100028.
View in: PubMed

Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. Immunity. 2019 12 17; 51(6):1043-1058.e4.
View in: PubMed

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
View in: PubMed

Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation. Blood Adv. 2019 11 12; 3(21):3419-3431.
View in: PubMed

Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019 09 25; 10(1):4346.
View in: PubMed

PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat Immunol. 2019 10; 20(10):1335-1347.
View in: PubMed

Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proc Natl Acad Sci U S A. 2019 08 20; 116(34):16971-16980.
View in: PubMed

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 10 15; 25(20):6080-6088.
View in: PubMed

Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2019 Jul; 571(7766):E10.
View in: PubMed

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity. 2019 06 18; 50(6):1498-1512.e5.
View in: PubMed

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
View in: PubMed

Blockade of RGMb inhibits allergen-induced airways disease. J Allergy Clin Immunol. 2019 07; 144(1):94-108.e11.
View in: PubMed

Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer. 2019 05 01; 144(9):2266-2278.
View in: PubMed

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
View in: PubMed

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019 Mar; 68(3):421-432.
View in: PubMed

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
View in: PubMed

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-? and IL-12. Immunity. 2018 12 18; 49(6):1148-1161.e7.
View in: PubMed

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer. 2018 11; 119(10):1223-1232.
View in: PubMed

Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2019 01 01; 25(1):290-299.
View in: PubMed

Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight. 2018 09 20; 3(18).
View in: PubMed

CD160 Stimulates CD8+ T Cell Responses and Is Required for Optimal Protective Immunity to Listeria monocytogenes. Immunohorizons. 2018 08 27; 2(7):238-250.
View in: PubMed

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018 10; 24(10):1550-1558.
View in: PubMed

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res. 2018 10; 6(10):1234-1245.
View in: PubMed

Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. J Immunol. 2018 08 01; 201(3):971-981.
View in: PubMed

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018 07 26; 174(3):549-563.e19.
View in: PubMed

PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunol Res. 2018 08; 6(8):921-929.
View in: PubMed

TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. JCI Insight. 2018 04 19; 3(8).
View in: PubMed

Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci U S A. 2018 05 01; 115(18):4749-4754.
View in: PubMed

TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 2018; 7(7):e1442999.
View in: PubMed

Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function. J Immunol. 2018 04 15; 200(8):2592-2602.
View in: PubMed

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018 03; 4(3):eaar2766.
View in: PubMed

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018 01 22; 20(2):225-235.
View in: PubMed

Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep. 2018 01 09; 8(1):208.
View in: PubMed

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017 11 23; 8(1):1747.
View in: PubMed

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018 01 04; 553(7686):91-95.
View in: PubMed

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
View in: PubMed

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
View in: PubMed

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunol Res. 2017 11; 5(11):1046-1055.
View in: PubMed

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res. 2017 11 15; 77(22):6353-6364.
View in: PubMed

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017 11 30; 130(22):2420-2430.
View in: PubMed

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 2017 09 11; 32(3):377-391.e9.
View in: PubMed

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017 10; 7(10):1098-1115.
View in: PubMed

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017 06; 5(6):480-492.
View in: PubMed

Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. Sci Rep. 2017 05 12; 7(1):1878.
View in: PubMed

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017 05 10; 9(389).
View in: PubMed

Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017 10; 198(4):817-823.
View in: PubMed

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol. 2017 08; 12(8):1268-1279.
View in: PubMed

Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol. 2017 Jun 01; 35(16):1836-1844.
View in: PubMed

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017 04 03; 214(4):895-904.
View in: PubMed

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017 03 31; 355(6332):1423-1427.
View in: PubMed

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204.
View in: PubMed

Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2017 02; 28(2):167-176.
View in: PubMed

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22; 7(47):76565-76576.
View in: PubMed

5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer. 2016; 4:65.
View in: PubMed

Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction. J Allergy Clin Immunol. 2017 May; 139(5):1468-1477.e2.
View in: PubMed

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016 09 15; 537(7620):417-421.
View in: PubMed

Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016 06 16; 1(9):e87415.
View in: PubMed

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
View in: PubMed

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016 07 01; 126(7):2642-60.
View in: PubMed

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep. 2016 06 10; 6:27702.
View in: PubMed

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016 Jun 07; 7(23):34341-55.
View in: PubMed

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016 08 10; 34(23):2698-704.
View in: PubMed

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget. 2016 May 31; 7(22):32925-32.
View in: PubMed

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016 05 17; 44(5):955-72.
View in: PubMed

Learning from PD-1 Resistance: New Combination Strategies. Trends Mol Med. 2016 06; 22(6):448-451.
View in: PubMed

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 08; 66(8):1463-1473.
View in: PubMed

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016 08 10; 34(23):2690-7.
View in: PubMed

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22.
View in: PubMed

Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol. 2016 Apr; 40(4):443-53.
View in: PubMed

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016 Mar 29; 7(13):17194-211.
View in: PubMed

Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016 05 20; 34:539-73.
View in: PubMed

Repulsive Guidance Molecule b (RGMb) Is Dispensable for Normal Gonadal Function in Mice. Biol Reprod. 2016 Apr; 94(4):78.
View in: PubMed

Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer. 2016; 2:16002.
View in: PubMed

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501.
View in: PubMed

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016 Feb 16; 44(2):343-54.
View in: PubMed

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 01; 76(5):999-1008.
View in: PubMed

LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. J Immunol. 2016 Mar 01; 196(5):2085-94.
View in: PubMed

Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):456-65.
View in: PubMed

Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016 Feb 18; 127(7):869-81.
View in: PubMed

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN? That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2016 Mar 01; 76(5):1031-43.
View in: PubMed

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35.
View in: PubMed

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in: PubMed

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res. 2015 Dec; 3(12):1308-15.
View in: PubMed

MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res. 2016 Jan; 4(1):33-40.
View in: PubMed

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med. 2015 Sep 21; 212(10):1603-21.
View in: PubMed

Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016 12; 65(12):1973-1980.
View in: PubMed

BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. Oncotarget. 2015 Aug 14; 6(23):19445-55.
View in: PubMed

Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015 Aug; 1(5):653-61.
View in: PubMed

Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015 Aug; 14(8):561-84.
View in: PubMed

Defective TFH Cell Function and Increased TFR Cells Contribute to Defective Antibody Production in Aging. Cell Rep. 2015 Jul 14; 12(2):163-71.
View in: PubMed

Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1123-1129.
View in: PubMed

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64.
View in: PubMed

A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. Clin Cancer Res. 2015 May 15; 21(10):2201-3.
View in: PubMed

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther. 2015 Apr 01; 37(4):764-82.
View in: PubMed

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015 Mar 26; 6:6692.
View in: PubMed

B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015 05 21; 125(21):3335-46.
View in: PubMed

Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
View in: PubMed

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
View in: PubMed

ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity. 2015 Mar 17; 42(3):538-51.
View in: PubMed

Interferon-?-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015 Jun; 4(6):e1008824.
View in: PubMed

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
View in: PubMed

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):3031-40.
View in: PubMed

Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015 Mar 27; 290(13):8110-20.
View in: PubMed

Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. J Gen Virol. 2015 Jun; 96(Pt 6):1463-1477.
View in: PubMed

The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015 Jan; 5(1):16-8.
View in: PubMed

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22; 372(4):311-9.
View in: PubMed

Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014 Dec; 38(12):1715-23.
View in: PubMed

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27; 515(7528):577-81.
View in: PubMed

OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol. 2015 Jan 01; 194(1):125-133.
View in: PubMed

CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep. 2014 Nov 06; 9(3):1075-88.
View in: PubMed

Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58.
View in: PubMed

Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med. 2014 Aug 25; 211(9):1905-18.
View in: PubMed

Comment on "Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection". J Immunol. 2014 Jul 15; 193(2):467.
View in: PubMed

Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12.
View in: PubMed

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
View in: PubMed

Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014 May 12; 25(5):590-604.
View in: PubMed

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
View in: PubMed

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014 May 05; 211(5):943-59.
View in: PubMed

Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses. PLoS One. 2014; 9(1):e87617.
View in: PubMed

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response. Cancer Res. 2014 Jan 15; 74(2):633-4; discussion 635.
View in: PubMed

Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. J Virol. 2014 Mar; 88(5):2508-18.
View in: PubMed

PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One. 2013; 8(10):e77780.
View in: PubMed

Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology. 2014 Feb; 146(2):550-61.
View in: PubMed

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec; 3(12):1355-63.
View in: PubMed

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013 Oct 24; 122(17):3062-73.
View in: PubMed

DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8? T cells independently of PD-1 and PD-L1. Int Immunol. 2013 Nov; 25(11):651-60.
View in: PubMed

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A. 2013 Sep 10; 110(37):15001-6.
View in: PubMed

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013 Dec 01; 73(23):6900-12.
View in: PubMed

Costimulatory genes: hotspots of conflict between host defense and autoimmunity. Immunity. 2013 Jun 27; 38(6):1083-5.
View in: PubMed

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
View in: PubMed

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013 Jun; 123(6):2604-15.
View in: PubMed

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013 Jul 01; 19(13):3462-73.
View in: PubMed

T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death. J Allergy Clin Immunol. 2013 Aug; 132(2):414-25.e6.
View in: PubMed

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013 Jun 15; 73(12):3591-603.
View in: PubMed

Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A. 2013 Jul 02; 110(27):E2480-9.
View in: PubMed

CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival. PLoS One. 2013; 8(4):e60391.
View in: PubMed

TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog. 2013 Mar; 9(3):e1003232.
View in: PubMed

Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med. 2013 Apr; 19(4):494-9.
View in: PubMed

Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans. J Leukoc Biol. 2013 Jun; 93(6):825-36.
View in: PubMed

Down-regulation of CTLA-4 by HIV-1 Nef protein. PLoS One. 2013; 8(1):e54295.
View in: PubMed

TIM-4, expressed by medullary macrophages, regulates respiratory tolerance by mediating phagocytosis of antigen-specific T cells. Mucosal Immunol. 2013 May; 6(3):580-90.
View in: PubMed

Cell-intrinsic abrogation of TGF-ß signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J Immunol. 2012 Oct 15; 189(8):3936-46.
View in: PubMed

Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses. Eur J Immunol. 2012 Sep; 42(9):2343-53.
View in: PubMed

CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 Feb; 62(2):347-57.
View in: PubMed

PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest. 2012 May; 122(5):1712-6.
View in: PubMed

Binding of hepatitis A virus to its cellular receptor 1 inhibits T-regulatory cell functions in humans. Gastroenterology. 2012 Jun; 142(7):1516-25.e3.
View in: PubMed

Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell. 2012 Feb 17; 148(4):739-51.
View in: PubMed

A new therapeutic strategy for malaria: targeting T cell exhaustion. Nat Immunol. 2012 Jan 19; 13(2):113-5.
View in: PubMed

Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A. 2011 Dec 27; 108(52):21182-7.
View in: PubMed

Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol. 2011 Oct 01; 187(7):3466-74.
View in: PubMed

Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity. 2011 Aug 26; 35(2):285-98.
View in: PubMed

4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol. 2011 Aug 15; 187(4):1634-42.
View in: PubMed

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011 Aug 01; 187(3):1097-105.
View in: PubMed

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011 Aug 01; 187(3):1113-9.
View in: PubMed

Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011 Jul 28; 118(4):965-74.
View in: PubMed

Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol. 2011 May; 31(5):1100-7.
View in: PubMed

Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol. 2011 Apr 01; 186(7):4200-12.
View in: PubMed

A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. J Clin Invest. 2011 Mar; 121(3):1111-8.
View in: PubMed

The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol. 2011 May; 85(9):4184-97.
View in: PubMed

Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol. 2011 Apr; 89(4):507-15.
View in: PubMed

TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells. J Immunol. 2010 Dec 01; 185(11):6839-49.
View in: PubMed

Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest. 2010 Nov; 120(11):3878-90.
View in: PubMed

Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. J Clin Invest. 2010 Nov; 120(11):3855-68.
View in: PubMed

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010 Oct; 16(10):1147-51.
View in: PubMed

Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. J Immunol. 2010 Nov 01; 185(9):5225-35.
View in: PubMed

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14733-8.
View in: PubMed

The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. Hum Pathol. 2010 Oct; 41(10):1486-94.
View in: PubMed

PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol. 2010 Sep; 130(9):2222-30.
View in: PubMed

TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010 May; 235(1):172-89.
View in: PubMed

Role of PD-1 in regulating acute infections. Curr Opin Immunol. 2010 Jun; 22(3):397-401.
View in: PubMed

T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010 Feb 15; 184(4):1918-30.
View in: PubMed

Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. Invest Ophthalmol Vis Sci. 2010 Jul; 51(7):3418-23.
View in: PubMed

Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol. 2009 Dec 15; 183(12):7898-908.
View in: PubMed

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009 Dec 21; 206(13):3015-29.
View in: PubMed

Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol. 2010 Feb; 84(4):2078-89.
View in: PubMed

Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol. 2010 Jan 01; 184(1):476-87.
View in: PubMed

Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection. J Virol. 2009 Sep; 83(18):9068-78.
View in: PubMed

Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10734-9.
View in: PubMed

Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol. 2009 Jul; 83(14):7305-21.
View in: PubMed

Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. Invest Ophthalmol Vis Sci. 2009 Oct; 50(10):4941-8.
View in: PubMed

The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev. 2009 May; 229(1):244-58.
View in: PubMed

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009 Feb; 5(2):e1000313.
View in: PubMed

Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol. 2009 Feb 15; 182(4):2102-12.
View in: PubMed

Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul Immunol Inflamm. 2009 Jan-Feb; 17(1):47-55.
View in: PubMed

IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20428-33.
View in: PubMed

Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009 Mar 12; 458(7235):206-10.
View in: PubMed

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009 Jan; 10(1):29-37.
View in: PubMed

Simian immunodeficiency virus (SIV)-specific CD8+ T-cell responses in vervet African green monkeys chronically infected with SIVagm. J Virol. 2008 Dec; 82(23):11577-88.
View in: PubMed

Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):15016-21.
View in: PubMed

Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood. 2008 Nov 01; 112(9):3679-87.
View in: PubMed

Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J Virol. 2008 Oct; 82(20):9808-22.
View in: PubMed

Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Natl Acad Sci U S A. 2008 Jul 29; 105(30):10275-6.
View in: PubMed

Interaction of human PD-L1 and B7-1. Mol Immunol. 2008 Aug; 45(13):3567-72.
View in: PubMed

Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood. 2008 Sep 01; 112(5):2149-55.
View in: PubMed

Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood. 2008 Sep 01; 112(5):1662-72.
View in: PubMed

ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol. 2008 Apr 15; 180(8):5448-56.
View in: PubMed

Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol. 2008 May; 82(10):5109-14.
View in: PubMed

Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med. 2008 Mar 17; 205(3):543-55.
View in: PubMed

Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology. 2008 Jun; 134(7):1927-37, 1937.e1-2.
View in: PubMed

The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A. 2008 Feb 19; 105(7):2658-63.
View in: PubMed

CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008 Feb; 9(2):176-85.
View in: PubMed

TIM gene family and their role in atopic diseases. Curr Top Microbiol Immunol. 2008; 321:201-15.
View in: PubMed

PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704.
View in: PubMed

High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol. 2008 Mar; 82(6):3154-60.
View in: PubMed

Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. Immunity. 2007 Dec; 27(6):941-51.
View in: PubMed

TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. 2007 Dec; 27(6):927-40.
View in: PubMed

Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007 Oct 30; 116(18):2062-71.
View in: PubMed

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol. 2007 Oct 15; 179(8):5064-70.
View in: PubMed

PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS. 2007 Oct 01; 21(15):2005-13.
View in: PubMed

Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007 Nov; 8(11):1246-54.
View in: PubMed

Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol. 2008 Feb; 126(2):140-7.
View in: PubMed

Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A. 2007 Sep 25; 104(39):15430-5.
View in: PubMed

The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol. 2007 Sep 15; 179(6):3672-9.
View in: PubMed

In-fusion assembly: seamless engineering of multidomain fusion proteins, modular vectors, and mutations. Biotechniques. 2007 Sep; 43(3):354-9.
View in: PubMed

A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo. J Immunol. 2007 Jul 15; 179(2):786-96.
View in: PubMed

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007 Jul; 27(1):111-22.
View in: PubMed

Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-beta signaling in activated T lymphocytes. Blood. 2007 Apr 01; 109(7):2944-52.
View in: PubMed

Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol. 2007 Jun; 81(11):5819-28.
View in: PubMed

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007 Mar; 8(3):239-45.
View in: PubMed

PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol. 2007 Mar 01; 178(5):2714-20.
View in: PubMed

Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), and the association of IgA with HAVCR1 enhances virus-receptor interactions. J Virol. 2007 Apr; 81(7):3437-46.
View in: PubMed

Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol. 2007 Mar; 81(6):2545-53.
View in: PubMed

Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006 Oct 02; 203(10):2223-7.
View in: PubMed

Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol. 2006 Sep 15; 177(6):4196-202.
View in: PubMed

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006 Sep 21; 443(7109):350-4.
View in: PubMed

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006 Jul; 30(7):802-10.
View in: PubMed

Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J Immunol. 2006 Jun 15; 176(12):7263-71.
View in: PubMed

Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006 Apr 17; 203(4):883-95.
View in: PubMed

The ICOS-ligand B7-H2, expressed on human type II alveolar epithelial cells, plays a role in the pulmonary host defense system. Eur J Immunol. 2006 Apr; 36(4):906-18.
View in: PubMed

PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol. 2006 Jan; 36(1):58-64.
View in: PubMed

Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006 Feb 09; 439(7077):682-7.
View in: PubMed

Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol. 2005 Dec 01; 175(11):7372-9.
View in: PubMed

Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood. 2006 Feb 15; 107(4):1528-36.
View in: PubMed

Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol. 2005 Sep 01; 175(5):3133-9.
View in: PubMed

CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol. 2005 Aug 01; 175(3):1558-65.
View in: PubMed

TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol. 2005 May; 6(5):447-54.
View in: PubMed

The B7 family revisited. Annu Rev Immunol. 2005; 23:515-48.
View in: PubMed

Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood. 2005 Apr 15; 105(8):3372-80.
View in: PubMed

RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell. 2004 Oct; 7(4):585-95.
View in: PubMed

Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat Immunol. 2004 Nov; 5(11):1149-56.
View in: PubMed

PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol. 2004 Aug; 230(2):89-98.
View in: PubMed

PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29):10691-6.
View in: PubMed

CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 2004 Jun 07; 199(11):1479-89.
View in: PubMed

An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 2004 May; 20(5):563-75.
View in: PubMed

Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003 Nov; 33(11):3117-26.
View in: PubMed

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003 Nov; 4(11):1102-10.
View in: PubMed

Immunology: hepatitis A virus link to atopic disease. Nature. 2003 Oct 09; 425(6958):576.
View in: PubMed

Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003 Oct; 33(10):2706-16.
View in: PubMed

The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest. 2003 Jul; 112(2):234-43.
View in: PubMed

The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol. 2003 Jun; 3(6):454-62.
View in: PubMed

The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J Biol Chem. 2003 Jun 13; 278(24):21930-7.
View in: PubMed

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003 Feb 01; 170(3):1257-66.
View in: PubMed

CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp. 2003; 252:67-88; discussion 88-91, 106-14.
View in: PubMed

Cutting edge: CD94/NKG2 is expressed on Th1 but not Th2 cells and costimulates Th1 effector functions. J Immunol. 2002 Nov 15; 169(10):5382-6.
View in: PubMed

Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002 Oct 21; 84(1):57-62.
View in: PubMed

Protect the killer: CTLs need defenses against the tumor. Nat Med. 2002 Aug; 8(8):787-9.
View in: PubMed

Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. 2002 Sep; 8(9):1024-32.
View in: PubMed

Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses. Int Immunol. 2002 May; 14(5):513-23.
View in: PubMed

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 2002 Apr; 9(2):133-45.
View in: PubMed

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002 03; 32(3):634-43.
View in: PubMed

The B7-CD28 superfamily. Nat Rev Immunol. 2002 Feb; 2(2):116-26.
View in: PubMed

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002 Jan 31; 415(6871):536-41.
View in: PubMed

Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol. 2001 Dec; 2(12):1174-82.
View in: PubMed

Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 2001 Dec; 2(12):1109-16.
View in: PubMed

Characterization of endogenous Chinese hamster ovary cell surface molecules that mediate T cell costimulation. Cell Immunol. 2001 Nov 01; 213(2):83-93.
View in: PubMed

CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001 Aug 01; 167(3):1245-53.
View in: PubMed

Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. Proc Natl Acad Sci U S A. 2001 Aug 14; 98(17):9778-83.
View in: PubMed

B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest. 2001 Apr; 107(7):881-7.
View in: PubMed

PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001 Mar; 2(3):261-8.
View in: PubMed

ICOS is critical for CD40-mediated antibody class switching. Nature. 2001 Jan 04; 409(6816):102-5.
View in: PubMed

Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J Immunol. 2000 Dec 01; 165(11):6091-8.
View in: PubMed

Examination of CD8+ T cell function in humans using MHC class I tetramers: similar cytotoxicity but variable proliferation and cytokine production among different clonal CD8+ T cells specific to a single viral epitope. J Immunol. 2000 Dec 01; 165(11):6214-20.
View in: PubMed

Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol. 2000 Nov 01; 165(9):5035-40.
View in: PubMed

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000 Oct 02; 192(7):1027-34.
View in: PubMed

Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol. 2000 Sep; 8(3):210-5.
View in: PubMed

p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med. 2000 Mar; 6(3):290-7.
View in: PubMed

Molecular characterisation of a NADH ubiquinone oxidoreductase subunit 5 from Schistosoma mansoni and inhibition of mitochondrial respiratory chain function by testosterone. Mol Cell Biochem. 1999 Dec; 202(1-2):149-58.
View in: PubMed

Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity. 1999 Dec; 11(6):689-98.
View in: PubMed

PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood. 1999 Oct 01; 94(7):2403-13.
View in: PubMed

Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol. 1999 Aug 01; 163(3):1363-70.
View in: PubMed

B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med. 1999 Mar 15; 189(6):919-30.
View in: PubMed

Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. Int Immunol. 1999 Mar; 11(3):407-16.
View in: PubMed

CD48-deficient mice have a pronounced defect in CD4(+) T cell activation. Proc Natl Acad Sci U S A. 1999 Feb 02; 96(3):1019-23.
View in: PubMed

Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J Immunol. 1999 Feb 01; 162(3):1223-6.
View in: PubMed

Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol. 1998 Sep 15; 161(6):2780-90.
View in: PubMed

The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol. 1998 Sep 15; 161(6):2708-15.
View in: PubMed

Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Proc Natl Acad Sci U S A. 1998 Sep 15; 95(19):11336-41.
View in: PubMed

The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas. Am J Pathol. 1998 Jul; 153(1):255-62.
View in: PubMed

Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol. 1998 Feb 01; 160(3):1532-8.
View in: PubMed

In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood. 1997 Dec 01; 90(11):4297-306.
View in: PubMed

Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. J Immunol. 1997 Nov 15; 159(10):4799-805.
View in: PubMed

Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science. 1997 Oct 03; 278(5335):124-8.
View in: PubMed

Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol. 1997 Oct 01; 159(7):3156-67.
View in: PubMed

Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones. J Immunol. 1997 Aug 15; 159(4):1669-75.
View in: PubMed

Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 1997 Jul 15; 90(2):549-61.
View in: PubMed

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997 May; 97(2):409-17.
View in: PubMed

B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. J Immunol. 1997 Mar 01; 158(5):2025-34.
View in: PubMed

B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997 Mar; 6(3):303-13.
View in: PubMed

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med. 1996 Dec; 2(12):1367-70.
View in: PubMed

Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11780-5.
View in: PubMed

Activation of human T cell lymphotropic virus type I-infected T cells is independent of B7 costimulation. J Immunol. 1996 Oct 01; 157(7):2932-8.
View in: PubMed

The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev. 1996 Oct; 153:5-26.
View in: PubMed

Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med. 1996 Aug 01; 184(2):365-76.
View in: PubMed

Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996 Jul 01; 88(1):41-8.
View in: PubMed

Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996 Jun 01; 87(11):4887-93.
View in: PubMed

A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. J Exp Med. 1996 Mar 01; 183(3):777-89.
View in: PubMed

B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996 Feb 01; 156(3):1126-31.
View in: PubMed

Differential expression of alternate mB7-2 transcripts. J Immunol. 1995 Dec 15; 155(12):5490-7.
View in: PubMed

Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8200-4.
View in: PubMed

Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995 May 01; 85(9):2507-15.
View in: PubMed

B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 1995 May; 2(5):523-32.
View in: PubMed

CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995 Apr 01; 85(7):1903-12.
View in: PubMed

The critical role of CD28 signalling in the prevention of human T-cell anergy. Res Immunol. 1995 Mar-Apr; 146(3):140-9.
View in: PubMed

CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A. 1995 Jan 31; 92(3):811-5.
View in: PubMed

Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5. J Immunol. 1994 Dec 01; 153(11):5038-48.
View in: PubMed

Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994 Nov 15; 84(10):3261-82.
View in: PubMed

Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science. 1994 Nov 11; 266(5187):1039-42.
View in: PubMed

CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 1994 Nov 01; 180(5):1665-73.
View in: PubMed

Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol. 1994 Oct; 6(5):797-807.
View in: PubMed

Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. J Immunol. 1994 Aug 15; 153(4):1421-9.
View in: PubMed

Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A. 1994 Aug 02; 91(16):7663-7.
View in: PubMed

A negative regulatory function of B7 revealed in B7-1 transgenic mice. Immunity. 1994 Aug; 1(5):415-21.
View in: PubMed

Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med. 1993 Dec 01; 178(6):2185-92.
View in: PubMed

Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A. 1993 Dec 01; 90(23):11059-63.
View in: PubMed

[Failing B7 costimulation engenders a peripheral clonal T-cell anergy in a human antigen-specific model]. Schweiz Med Wochenschr. 1993 Nov 27; 123(47):2255-6.
View in: PubMed

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993 Nov 05; 262(5135):909-11.
View in: PubMed

Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science. 1993 Nov 05; 262(5135):907-9.
View in: PubMed

The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion. Cell Immunol. 1993 Nov; 152(1):249-60.
View in: PubMed

B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med. 1993 Nov 01; 178(5):1753-63.
View in: PubMed

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A. 1993 Jul 15; 90(14):6586-90.
View in: PubMed

Identification, by protein sequencing and gene transfection, of sgp-60 as the murine homologue of CD48. Proc Natl Acad Sci U S A. 1993 Apr 15; 90(8):3418-22.
View in: PubMed

Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. Eur J Immunol. 1993 Jan; 23(1):283-6.
View in: PubMed

Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol. 1992 Dec 15; 149(12):3802-8.
View in: PubMed

CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol. 1992 Dec 15; 149(12):3795-801.
View in: PubMed

Early signaling defects in human T cells anergized by T cell presentation of autoantigen. J Exp Med. 1992 Jul 01; 176(1):177-86.
View in: PubMed

Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci U S A. 1992 May 01; 89(9):4210-4.
View in: PubMed

The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21. Blood. 1992 Jan 15; 79(2):489-94.
View in: PubMed

The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the beta-galactoside alpha 2,6-sialyltransferase. J Cell Biol. 1992 Jan; 116(2):423-35.
View in: PubMed

Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci U S A. 1992 Jan 01; 89(1):271-5.
View in: PubMed

All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood. 1991 Dec 15; 78(12):3275-80.
View in: PubMed

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991 Nov 28; 325(22):1525-33.
View in: PubMed

Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 1991 Oct 15; 137(2):429-37.
View in: PubMed

Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med. 1991 Sep 01; 174(3):625-31.
View in: PubMed

B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A. 1991 Aug 01; 88(15):6575-9.
View in: PubMed

Follicular dendritic cells contain a unique gene repertoire demonstrated by single-cell polymerase chain reaction. Blood. 1991 Feb 15; 77(4):787-91.
View in: PubMed

Definition of T-cell specific DNA-binding factors that interact with a 3'-silencer in the CD4+ T-cell gene Rpt-1. Gene. 1989 Dec 28; 85(2):461-9.
View in: PubMed

Activation primes human B lymphocytes to respond to heat shock. J Exp Med. 1989 Nov 01; 170(5):1763-8.
View in: PubMed

B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989 Oct 15; 143(8):2714-22.
View in: PubMed

Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med. 1989 07 01; 170(1):145-61.
View in: PubMed

Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med. 1989 Jun 01; 169(6):2043-58.
View in: PubMed

Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989 May; 83(5):1512-8.
View in: PubMed

Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol. 1989 May; 19(5):849-55.
View in: PubMed

Cloning and expression of a gamma-interferon-inducible gene in monocytes: a new member of a cytokine gene family. Int Immunol. 1989; 1(4):388-97.
View in: PubMed

Studies of in vitro activated CD5+ B cells. Blood. 1989 Jan; 73(1):202-8.
View in: PubMed

Pre-exposure of human B cells to recombinant IL-1 enhances subsequent proliferation. J Immunol. 1988 Nov 15; 141(10):3398-404.
View in: PubMed

rpt-1, an intracellular protein from helper/inducer T cells that regulates gene expression of interleukin 2 receptor and human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1988 Apr; 85(8):2733-7.
View in: PubMed

B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol. 1987 Nov 15; 139(10):3260-7.
View in: PubMed

Cloning and characterization of a novel T cell activation gene. J Immunol. 1987 Nov 01; 139(9):3126-31.
View in: PubMed